A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.
- DOI
- 10.1158/1078-0432.ccr-26-0273
- Published
- 2026 Sep 1
- Container
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/1078-0432.ccr-26-0273,
title = {A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.},
author = {Chon HJ and Heo J and Kim DY and Lim HY and Macarulla T and Gomez Martín C and Moreno V and Reig M and Ryu MH and Yoon JH and Baumann P and Bhoi S and Jensen M and Tunblad K and Wallberg H and Öberg F and Evans TRJ},
year = {2026},
journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
doi = {10.1158/1078-0432.ccr-26-0273},
url = {https://doi.org/10.1158/1078-0432.ccr-26-0273}
}RIS
TY - JOUR TI - A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma. AU - Chon HJ AU - Heo J AU - Kim DY AU - Lim HY AU - Macarulla T AU - Gomez Martín C AU - Moreno V AU - Reig M AU - Ryu MH AU - Yoon JH AU - Baumann P AU - Bhoi S AU - Jensen M AU - Tunblad K AU - Wallberg H AU - Öberg F AU - Evans TRJ PY - 2026 JO - Clinical cancer research : an official journal of the American Association for Cancer Research DO - 10.1158/1078-0432.ccr-26-0273 UR - https://doi.org/10.1158/1078-0432.ccr-26-0273 ER -
APA
HJ, C., J, H., DY, K., HY, L., T, M., C, G. M., V, M., M, R., MH, R., JH, Y., P, B., S, B., M, J., K, T., H, W., F, Ö., & TRJ, E. (2026). A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-0273
Source records
- pubmed · retrieved 2026-09-26T11:30:32.576Z